RxTally.CA — Canadian maple leaf logoClarity in every comparison.
Health Canada recalls

Dr. Reddy’s semaglutide: August impurity recall

An impurity recall requires attention to the affected product records and lots. It should not be confused with another manufacturer’s device-display notice. Health Canada’s original record is the place to confirm the scope and current instructions before drawing conclusions from a summary.

By RxTally2 min readSource date:

Key takeaways

  • This notice concerns an impurity issue, not a dose-display problem.
  • Check both the DIN and affected lot list.
  • An earlier approval or launch article does not replace a recall notice.

Affected product records

Health Canada’s notice identifies Dr. Reddy’s Semaglutide Injection, DINs 02567806 and 02567814, for an out-of-specification impurity. The notice provides the affected lot numbers; compare these with the package rather than relying on the ingredient name alone.

What the notice advises

Verify whether the product is affected and consult a healthcare provider before discontinuing it or about health concerns. Follow the current official instructions and contact the recalling firm with recall questions.

About the date

The source labels August 27, 2026 as its original publication date, while its last-updated field shows August 26. Our archive uses the explicitly labelled original publication date.

Why different semaglutide recalls must stay separate

Two notices can be published on the same day and share an ingredient while describing different products and risks. Combining them into one generic headline makes it harder to identify the relevant action.

Use the manufacturer, product name, DIN and issue description to distinguish the records. Keep the official notice open while you check a package, and ask the pharmacist to help if any identifier does not match.

A practical record for your pharmacy conversation

Prepare the product name, lot, expiry date and notice link. The expiry date can help identify the package, but it is not a substitute for the lot number. Note where the medicine was dispensed so the appropriate pharmacy can advise you.

Ask what the notice requires for your package and how ongoing care should be handled. Do not infer an acceptable impurity level or an individual health outcome from the recall headline. Questions about symptoms or treatment belong with a healthcare professional.

Frequently asked questions

Can a package be affected even if it is not expired?

Recall scope is determined by the notice, including product and lot details. Expiry alone cannot rule a package in or out.

Is the earlier approval announcement still accurate?

It remains a historical approval event. Current safety and availability questions require later records as well.

Sources & further reading

View source notes for this article →

The date above identifies the source announcement or article, not the publication date of this RxTally explanation.

Related reading